Artobiloxanthone (Compound AA3) exhibits antitumor activity, particularly against oral squamous cell carcinoma (OSCC). It inhibits the Akt/mTOR and STAT3 pathways, thereby suppressing the proliferation of SAS and T.Tn cells with IC50 values of 11 and 22 μM, respectively, as well as cancer cell migration. Artobiloxanthone induces cell apoptosis in OSCC by activating caspase3/9 and causes cell cycle arrest at the S phase.